Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib

Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.

Suit Asks J&J CEO to Return Part of 2010 Pay

J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.

Study Results Boost Analyst’s Forecast for Novartis Drug

An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.